December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.37 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
40 41 Next >
News headline image
Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold ↗
The company was testing the drug in multiple sclerosis and myasthenia gravis. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Sanofi Shares Are Falling Today ↗
 
Via Benzinga
News headline image
Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline' ↗
The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news,... 
Via Benzinga
News headline image
Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients ↗
 
Via Benzinga
News headline image
FDA Accepts Regeneron, Sanofi's Filing For Review In Skin Disease ↗
The U.S. 
Via Benzinga
News headline image
Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes ↗
The companies' shot was more than 93% effective in previously infected people. 
Via Investor's Business Daily
News headline image
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24 ↗
Reuters 
Via Benzinga
News headline image
Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron ↗
 
Via Benzinga
News headline image
This Pharmaceutical Company Is Moving Beyond CBD ↗
The applications for cannabidiol (CBD) and cannabinoid-based therapeutics are many. Many novel treatments have been, and are continuing to be, discovered using these compounds. The industry is huge... 
Via Benzinga
News headline image
Jupiter Wellness Believes Its Latest Strategic Acquisition Could Be A Significant Boon To Compete In The Medical Cannabis Industry ↗
Companies like Tilray Inc. (NASDAQ: TLRY) and Cara Therapeutics Inc. 
Via Benzinga
News headline image
Clovis Oncology (CLVS) Stock Gains 20% on Tumor Trials, Buyout Hopes ↗
Today has been another strong one for investors in Clovis Oncology and CLVS stock, with this company surging another 20% in today's session. 
Via InvestorPlace
News headline image
Clovis Oncology (CLVS) Stock Rallies on Buyout Rumors ↗
Pharmaceutical startup CLVS stock is climbing 25% higher today on rumors that the cancer drug maker has become a takeover target. 
Via InvestorPlace
News headline image
Morning Brief: Top Financial Stories Dominating on Monday, June 13 ↗
CNBC JPMorgan Remains Bullish On Alibaba And Other Chinese Stocks - Here’s Why 
Via Benzinga
News headline image
Sanofi-GSK's Next-Gen COVID-19 Booster Shows Potential Against Variants Of Concern ↗
 
Via Benzinga
News headline image
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit ↗
The conversation around obesity is changing. Two diabetes drug makers are at the forefront. 
Via Investor's Business Daily
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
News headline image
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children ↗
The U.S. 
Via Benzinga
News headline image
CStone Pharma Replaces Chairman Amid Huge Losses, Irregular Investment ↗
Key Takeaways: CStone brought four products to market last year, and its losses have surged due to growing R&D and sales spending Appointment of chairman with close ties... 
Via Benzinga
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
News headline image
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More ↗
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer ↗
Regeneron secured the global rights to Sanofi-partnered Libtayo. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood... 
Via FinancialNewsMedia
News headline image
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More ↗
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
News headline image
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule ↗
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc. 
Via Benzinga
News headline image
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
7 Penny Stocks With 10x Potential This Year ↗
These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward. 
Via InvestorPlace
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.